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CORRESPONDENCE
Re: Vitamin A Analogue for
Breast Cancer Prevention: a
Grade of F or Incomplete?
We were annoyed by the disparaging
title given to the editorial written by S.
Piantadosi (1) on our breast cancer pre-
vention trial with fenretinide, which was
published in the November 3 issue of the
Journal (2). First, we feel that the title is
not consistent with the editorial content
itself (who gives an F grade to a “well
designed and conducted study”?). In ad-
dition, the title is in sharp contradiction
with Journal policy to publish only ar-
ticles of major importance. Our disap-
pointment was increased after learning
that, as a result of this title, several me-
dia outlets have dismissed our study as
being one of poor quality. In the current
publicity-dominated era, the choice of
this title is at best unscrupulous, if not
dictated by reasons that have little to do
with science.
It is a shame that the irresistible
temptation of adding a sensationalist
title has overcome a more reasonable re-
view of our study, while we think we
have honestly addressed the limitations
of our work in the paper. Contrary to Dr.
Piantadosi’s doubts, we had clearly
stated in the article that, among the
dozen possible interactions, we tested
only the one between fenretinide treat-
ment and menopausal status because
this interaction has strong biologic sup-
port. This support came not only from
our previous observations that plasma
insulin-like growth factor-I (IGF-I) lev-
els behaved with the same pattern fol-
lowing fenretinide treatment [refs. (27)
and (28) of our paper], but also from the
well-established notion that premeno-
pausal and postmenopausal breast can-
cer are different diseases that receive
different treatments and have different
risk factors, some of which, like body
mass index, interact in a qualitative
manner with menopausal status [refs.
(39–41) of our paper].
Since we believe that biologic plau-
sibility should drive statistics and not
vice versa, we feel that leaving this in-
teraction untested would have missed
some very important information. It is
argued that our study was not powered
to test such an interaction. Consistently,
we have not recommended treating pre-
menopausal women with fenretinide but
simply suggested implementing further
studies to address the new hypotheses
that are generated by our study. Our pru-
dent attitude is demonstrated by the fact
that, in contrast to one reviewer’s ad-
vice, we have not pooled contralateral
breast cancer and ipsilateral breast can-
cer events in a single figure. While this
combination would have certainly pro-
vided more powerful statistical support
for the benefit of fenretinide in pre-
menopausal women, such a combined
analysis had not been planned before the
study was conducted.
The bottom line is that the fenretinide
trial is one of the few large cancer pre-
vention trials ever performed and is by
far the largest clinical study that tests a
retinoid for breast cancer prevention.
Awarding an F grade to our pioneering
study without any sound scientific argu-
ment is arrogant, cynical, and uselessly
mortifying for the nearly 3000 women
who took part in the study for an average
of 8 years, for the many investigators
and support personnel who gave their
time and effort for such a long period of
time, for the reviewers who recom-
mended National Cancer Institute fund-
ing for three consecutive periods for a
total of 9 years, and last, but not least,
for the U.S. and Italian taxpayers and
contributors who made the resources
available.
We thought it appropriate to submit
our paper to the Journal in view of the
above-mentioned reasons. We are ex-
tremely disappointed by the Journal’s
decision to publish our paper alongside
this destructive editorial without inform-
ing us until the moment of its publica-
tion. We are sorry the Journal missed an
opportunity to begin a fruitful discus-
sion on the complex issues related to
cancer prevention trials.
UMBERTO VERONESI
GIUSEPPE DE PALO
ETTORE MARUBINI
ALBERTO COSTA
LUIGI MARIANI
FRANCA FORMELLI
ANDREA DECENSI
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Both the report on the “Randomized
Trial of Fenretinide to Prevent Second
Breast Malignancy in Women With
Early Breast Cancer” and the accompa-
nying editorial impressed me as
thoughtful presentations and discussions
of the complex results reported (1,2).
Why then the sensationalist title for the
editorial? If this title was the one chosen
by the editorialists, the Journal should
have insisted on a more objective title. If
the title was selected by the Journal,
then shame on the Journal. Certainly the
dismissal by the media of this trial as a
poorly done study serves no one well.
Doing clinical research is hard enough
without our most cited (best ?) journal in
cancer research resorting to “yellow
journalism.”
FRANK L. MEYSKENS, JR.
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RESPONSE
It’s not often that a favorable edito-
rial gets taken to task by the recipient. I
hope that other readers did not miss my
points or get them backwards, as
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Veronesi et al. did. Careful reading, time
to digest, and perhaps even e-mail might
have prevented their perversion. In any
case, I will ignore the ad hominem in
their letter in favor of the following
comments. Dr. Meyskens objects to the
title alone, but oddly didn’t reconsider
it, even after finding the content
“thoughtful.” His concerns are obviated
below.
First, the title. It clearly interrogates
“vitamin A analogue” (fenretinide) as a
drug, not the fenretinide trial or the work
of the authors. Since when is querying
the efficacy of a drug considered “sen-
sationalist” and “yellow journalism”? It
is only because the trial was well done,
as I said explicitly, that one can make
inferences about the drug. The reason-
ableness of this title is further empha-
sized below.
Second, the methodologic danger as I
see it is that the findings of the trial with
respect to the treatment–covariate inter-
action will be dismissed outright by
many. This dismissal is because of the
small magnitude, marginal significance,
and post hoc pedigree of the test. Those
who take such a harsh view would rate
fenretinide as a proven failure. The edi-
tors of the Journal correctly saw this as
an issue, which is why a trial statistician
was asked to comment. My editorial ar-
gued against dismissal, again explicitly.
Third, are Veronesi et al. (or Mey-
skens) more heavily invested in the re-
ality of a beneficial fenretinide effect
than the manuscript suggests? It is
hardly proven by the putative biologic
mechanism—but it is given support. It is
my opinion, a statement of which is the
right and purpose of an editorial, that
additional empirical data will be re-
quired to establish the truth of the ob-
servation. Hence, my assessment that
the tale of fenretinide is incomplete.
Even Veronesi et al. say in their com-
plaint that we need further studies to ad-
dress the new hypothesis. So, asking if
fenretinide is a failure or if the informa-
tion is merely incomplete captures the
essence of the issue.
Finally, I am not responsible for the
poor reading habits of journalists.
Perhaps with these points empha-
sized, Veronesi et al. can regain their
composure, recognize a serious inferen-
tial issue, appreciate a favorable review
of their study, and continue with the im-
portant work of developing prevention
strategies for breast cancer.
STEVEN PIANTADOSI
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